Cargando…

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. In clinical studies, dupilumab reduced the risk of severe asthma exacerbations, and improved forced expiratory volume i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gall, Rebecca, Jain, Neal, Soong, Weily, Settipane, Russell A., Xia, Changming, Zhang, Yi, Haselkorn, Tmirah, Jacob-Nara, Juby A., Siddiqui, Shahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988992/ https://www.ncbi.nlm.nih.gov/pubmed/36626107 http://dx.doi.org/10.1007/s12325-022-02399-5

Ejemplares similares

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
por: Gevaert, Philippe, et al.
Publicado: (2023)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
por: Hanania, Nicola A, et al.
Publicado: (2022)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
por: De Prado Gomez, Lucia, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
por: Bagel, Jerry, et al.
Publicado: (2022)

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022)

Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States
por: Graham, Robert J., et al.
Publicado: (2023)

Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
por: Wechsler, Michael E., et al.
Publicado: (2021)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
por: Rathinam, Kiran Kumar, et al.
Publicado: (2019)

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Wencel, Mark L., et al.
Publicado: (2018)

Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort
por: Chipps, Bradley E., et al.
Publicado: (2012)

Incidence of anaphylaxis and accidental peanut exposure: A systematic review
por: Muraro, Antonella, et al.
Publicado: (2021)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Successful treatment with dupilumab for mucus plugs in severe asthma
por: Anai, Moriyasu, et al.
Publicado: (2022)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma
por: Soong, Weily, et al.
Publicado: (2021)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
por: Campisi, Raffaele, et al.
Publicado: (2021)

Epidemiology of Vasomotor Rhinitis
por: Settipane, Russell A
Publicado: (2009)

Dupilumab in the management of moderate-to-severe asthma: the data so far
por: Barranco, Pilar, et al.
Publicado: (2017)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
por: Zhang, Li, et al.
Publicado: (2021)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ab3pq2n7divh19cikbkg481rfd